Creso Pharma

Creso Pharma carries a Neutral rating at a 40 composite score and 3/5 conviction. The regulatory pillar leads at 56, supported by Australia’s 72 jurisdiction posture and an 80 enforcement subscore, with no enforcement hits recorded. Market contributes 40 despite the absence of an available quote, while fundamentals score 33 and editorial scores 30. The lower pillars restrain the stronger jurisdictional setup: filing cadence scores only 25, and CIN newsroom coverage records no newsroom or brief activity. The resulting profile reflects regulatory support offset by weak economics, limited disclosure momentum, and sparse external visibility.

Licensed fundamentals data show year-over-year revenue growth of roughly 44%, producing a strong 93.6 revenue-growth subscore. That expansion has not translated into operating leverage. Gross margin is only about 2.5%, corresponding to a 4.1 subscore, while operating margin stands near negative 217% and receives no subscore contribution. EBITDA remains negative at approximately $16.8 million, the cash-burn ratio is about 0.73, and the cash-runway subscore is 15. With market capitalization near $23.1 million and a 14.5 size-tier subscore, financial flexibility remains constrained under the stated stretched condition. Primary regulatory filings show no events across either the past 90 or 180 days and no latest filing date, leaving cadence as the principal drag within the otherwise strongest pillar. Institutional pricing feeds provide no current quote, reinforcing the market pillar’s limited informational support.

The clearest forward catalyst sits in regulatory disclosure rather than current profitability or trading data. Australia’s favorable jurisdiction posture and the absence of enforcement hits create the strongest foundation in the scorecard, but that strength delivers greater rating support only when accompanied by renewed filing activity. A fresh primary regulatory filing would improve transparency, strengthen the 25 cadence subscore, and provide measurable evidence that the company is converting jurisdictional advantages into corporate progress. Revenue growth already demonstrates demand momentum, yet low gross margin, deeply negative operating margin, negative EBITDA, and stretched financial condition keep the Neutral band intact. The single most important signal to watch is the appearance of a new primary regulatory filing that restores reporting cadence.